Naomi P. O'Grady, MD, *Editor* Sameer S. Kadri, MD, MS, *Editor*Infection occupies an overwhelming presence in the intensive care unit (ICU). Nearly half of the ICU patients worldwide are battling infection, and over two-thirds are prescribed antibiotics. Furthermore, this patient population we serve continues to grow in age, complexity, and vulnerability such that infection can easily tip the balance toward critical illness and death. Although outcomes from critical illness have improved over the years, patients with sepsis and septic shock continue to demonstrate unacceptably high mortality. The rise and fall of early goal-directed therapy for sepsis have renewed our realization of how important early recognition, prompt antibiotic delivery, and source control are for a good outcome. Therefore, it is not surprising that infectious disease consultation has been shown to improve outcomes in a number of infections in the critically ill.

The last decade has witnessed increased activity on the interface of infectious diseases and critical care that has fostered combined training pathways in these two subspecialties. This increased integration of specialties has contributed to dramatic decreases in central line--associated bloodstream infections, the expanding infrastructure nationwide for extracorporeal membrane oxygenation in severe acute respiratory distress syndrome from influenza and bacterial pneumonia, resurrecting the antibiotic pipeline, prioritizing antibiotic stewardship, and bolstering emerging technology for rapid identification of pathogens. At the same time, both specialties have been humbled by the advent of pan-drug-resistant bacteria and serious outbreaks of emerging viruses such as severe acute respiratory syndrome coronovirus, Middle East respiratory syndrome, and Ebola. We need a high degree of vigilance to detect, prepare for, and curb such epidemics, and we need to constantly appraise novel pathobiologic theories, biomarkers, and therapies as they emerge. Simply enhancing our repertoire of intensive monitoring, resuscitation, and organ support for the critically ill will not be enough. It behooves us to stay abreast with local epidemiologic and susceptibility patterns, know which infections to anticipate with the increasing use of various novel immunomodulatory and biologic therapies for cancer and inflammatory diseases, recognize when adjunctive therapies are warranted, when enhanced isolation is indicated, when clinical judgment supersedes a biomarker test result, and when the risk of discordant antimicrobial therapy trumps the risk of selective pressure and *Clostridium difficile* infection.

The following issue of *Infectious Disease Clinics of North America* is a compilation of articles that combine current evidence with the opinion of experts in the fields of infectious diseases and critical care. We have attempted to cover nuanced epidemiologic and management issues on this interface of these two specialties. The information provided in this issue can benefit health care providers at all stages of training and practice, and it is hoped, patients and public health at large.
